Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.

Xiaohui Niu(Peking University), Tao Li(Zhejiang Normal University), Wenzhi Bi(Chinese PLA General Hospital), Wangjun Yan(Shanghai Medical College of Fudan University), Yuhong Zhou(Sun Yat-sen University), Feng Wei(Peking University), Zhaoming Ye(Second Affiliated Hospital of Zhejiang University), Chongqi Tu(Sichuan University), Jianmin Li(Qilu Hospital of Shandong University), Dong Wang(Zhejiang Chinese Medical University), Xiaojing Zhang(Liaoning Cancer Hospital & Institute), Jianhua Lin(Wenzhou Medical University), Gang Huang(Hunan Cancer Hospital), Zhichao Tong(Klinikum rechts der Isar), Guochuan Zhang(Hebei Medical University), Jilong Yang(Tianjin Medical University Cancer Institute and Hospital), Jingnan Shen(Sun Yat-sen University), Zheng Guo(Tang Du Hospital), Hairong Xu(Peking University), Weitao Yao(Sichuan Cancer Hospital)
Journal of Clinical Oncology
May 20, 2021
Cited by 4


Related Papers